Amalgamated Financial’s Adaptive Biotechnologies ADPT Stock Holding History

Amalgamated Financial’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$346K	Buy	+24,913	New	+$392K	﹤0.01%	1673

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Amalgamated Financial's ADPT Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Adaptive Biotechnologies (ADPT) in Q1 2022: 24,913 shares worth $346K. The stake represents ﹤0.01% of the portfolio and ranks #1673 among its holdings.

221 funds tracked by Wall St. Rank hold ADPT as of Q1 2022.

Amalgamated Financial held 24,913 shares of Adaptive Biotechnologies worth $346K as of Q1 2022.
Adaptive Biotechnologies was a new Amalgamated Financial position in Q1 2022.
Adaptive Biotechnologies made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1673 holding.
221 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.